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Albumin is thought as an drug carrier for doxorubicin (DOX). The binding of doxorubicin to albumin was
studied on the surface of sporopolleninin (SP) to produce a new drug system based natural materials.
Human serum albumin (HSA) was immobilized on SPIONs in 20 mM Tris buffer, 7.4 of pH. Data showed
that binding amount of HSA has been found to be as 285.53 mg to the 25 mg of Sporopolleninin which
also bounded 319.76 mM of DOX. Binding of protein and drug to Sp were clariﬁed by SEM, EDX and FT-IR
analysis.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drugs based on proteins, peptides and oligonucleotides tend to
attract the greatest attention at present due to their potential to
treat chronic diseases [1]. The research is centered on overcoming
the main obstacle to the treatment of cancer by chemotherapy, i.e.,
the destruction of healthy tissue by the therapeutic agents [2].
Biocompatible polymeric based particles (BPs) as effective delivery
carriers of drugs has received considerable attention in recent
years because they possess the ability to deliver drugs to varied
areas of the body for sustained periods of time [3–6]. Biological
polymers with several properties such as good biological com-
patibility, nontoxicity and high hydrophilicity, comparing with
synthetic organic materials when used as drug carriers [5–9].
Suitable modiﬁcation and optimization of the form of the biolo-
gical polymer has to be determined to properly target the selected
polymer and its controlled release to the affected organs [10,11].
Naturally occurring polymers have garnered attention within the
scope of obtaining carriers capable of releasing therapeutic mo-
lecules to affected sites binding the targeted disease in a living
body [12,13].
Sporopollenin (Sp) represents a most promising biopolymer for
such controlled delivery and targeting, due to factors such as its
biocompatibility, low toxicity, and feasible biodegradabilityan open access article under the C
hemistry, Selcuk University,
.connected with easy elimination of carrier metabolites from the
body [14]. Sporopollenins, derived from the spores of Lycopodium
clavatum (Sp), contain carbon, hydrogen and oxygen, and it has the
stoichiometry C90H144027. The diameter of a Sp is typically
within the range of 5 mm to 250 mm and the material does not
swell to any measurable extent in aqueous or organic solvents [15].
Spores which are roughly spherical in shape produced by nonseed
bearing plants, for example ferns and mosses, as part of the pro-
cess of reproduction [16]. The same size and decorations of Sp
particles in a single species of plant makes possible to attach small
molecules such as ligand and drugs to the outside of complete
particles this morphology was regarded as being so applicable to
drug delivery [17]. For drug delivery, different particles modiﬁed
with protein have been widely reported [18] in particular, physical
or chemical modiﬁcation can improve the properties of particles in
different ways. Nevertheless, there are some drawbacks related to
their toxicity, biocompability and allergic affectivity. In drug de-
livery applications, naturally occurring Sp has been shown to be
non toxic to human endothelial cells and free of allergenic protein
epitopes which is crucial [19]. Because Lycopodium clavatum spores
have a number of advantages over conventional materials they
were chosen as a Np for the drug delivery used for this study.
Albumin is a versatile protein carrier biomaterial for much
therapeutics in treating a variety of diseases including cancer, ar-
thritis and diabetes and was considered an attractive drug carrier
for hydrophobic drugs [20]. Human serum albumin (HSA) has a
molecular weight of 66 kDa and highly soluble globular mono-
meric protein [21–23]. HSA is a multiple protein carrier for drugC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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biocompatible and biodegradable, so it can be preferentially taken
up by tumors as a nutrition ingredient [24]. Studies have indicated
that albumin based on particles have great potential in the smart
delivery of therapeutic agents.
This study focused on the albumin immobilized Sporopollenin
(Sp-HSA) for delivery of doxorubicin (DOX) to enhance target
ability. DOX as an anti-tumor model drug was loaded to Sp-HSA.
As expected, the prepared Sp-HSA system has shown high afﬁnity
for DOX.Fig. 1. Emission spectra and calibration curve of albumin from human serum at a
concentration range of 0,1–0,5 mg mL1.2. Materials and methods
2.1. Materials and chemicals
Sodium hydroxide (Z97%), hydrochloric acid (37%), tris (hy-
droxymethyl)-aminomethane (99.8–100.1%), ammonium hydro-
xide (25% w/w) and sodium chloride were obtained from Merck
(Germany). Sporopollenin was obtained from Fluka. Human serum
albumin was obtained from Sigma (USA). Doxorubicin was pro-
vided from Sigma Aldrich. All aqueous solutions and buffers were
prepared with deionized water via Millipore Milli-Q Plus water
puriﬁcation system.
2.2. Immobilization of albumin on sporopolleninin
Sp was mixed with a concentration of 1 mg mL1 of human
serum albumin (HSA) in 20 mM Tris, pH 7.4 at a particle con-
centration range of 5–25 mg mL1 [14]. Then, the heterogenous
solution was mixed for 2 h at 4 °C. Albumin immobilized spor-
opollenin was washed with Tris buffer for chemical analysis. Su-
pernatant was scanned for determination of binding amount of
albumin. The amount of immobilized protein was measured from
regression equation of calibration curve of the protein
(y¼404,81xþ501,65, r: 0.99) by using a Perkin-Elmer LS 55 Lu-
minescence Spectrophotometer (Waltham, USA). The emission
spectra were scanned at 280 and 342 nm of excitation and emis-
sion wavelengths [25].
2.3. DOX loading and releasing
1 mM of doxorubicin was dissolved in mL of 20 mM Tris–HCl
buffer (pH 7.4) [26]. The DOX solution was added to the 5–25 mg of
protein immobilized sporopollenin in 20 mM Tris–HCl buffer (pH
7.4) in order to measure DOX loading. DOX release from Sp-HSA
was studied via different buffer with a various pH at 60 rpm and
37 °C. The release behaviors of DOX-loaded albumin particles un-
der different pH (154 mM NaCl, pH:2.2; and 6; 20 mM Tris buffer,
pH: 7.4) were evaluated. The excitation and emission wavelengths
of the drug were also scanned at 480 nm and 560 nm by ﬂuores-
cence spectroscopy, respectively. The excitation and emission slit
width were both set to 10 nm. Loading amount of DOX to albumin-
Sp and release of the DOX from albumin-Sp were calculated from
calibration curve of DOX (y¼72, 282x þ125, 27, r: 0.99).
2.4. Instrumentation
FT-IR spectra were scanned on a Perkin Elmer spectrum 100
FTIR spectrometer (ATR). SEM images were obtained using a Zeiss
LS-10 ﬁeld emission SEM instrument equipped with an Inca En-
ergy 350 X-Max (Oxford Instruments) spectrometer. Samples were
sputter-coated with Au (60%) and Pd (40%) alloy using a Q150R
(Quorum Technologies) instrument.3. Results and discussions
3.1. Immobilization of albumin
A broad scale of materials such as chitosan, sporopollenin, mag-
netic nanoparticles and polymers by different functional groups have
been widely used in drug delivery systems [27–34]. Our group has
focus on development of drug carrier systems having proteins [26–34].
One of our previous studies has been on immobilization of he-
moglobin onto sporopollenin which was showed to be high afﬁnity to
the protein, so it is possible to develop a new drug delivery system
based on sporopollenin-protein [14]. Because, the use of protein in
drug carrier systems was very effective on bioavailability and reduc-
tion of side effects of the drugs in vivo [32–34].
The standard albumin solution was mixed with different
amount of sporopollenin particles. After binding of albumin to
particles, supernatant from the heterogeneous system was re-
moved and scanned with spectroﬂuorometer at 280 nm and
342 nm of excitation and emission wavelengths where exhibited
intrinsic ﬂuorescence of protein. The intrinsic ﬂuorescence of
protein comes from tryptophan and tyrosine residues in the al-
bumin's structure [35–37]. The emission spectrum for albumin
were shown in Fig. 1. The binding amount of the albumin was
calculated via the regression equation at a particles amount range
of 0.1 mg and 0.5 mg (Fig. 1). The binding amount of albumin was
increased with increase in the particles amount. Data showed that
285.53 mg of albuminwas bounded to the 25 mg of Sp in Tris buffer
(Fig. 2).
3.2. Releasing and loading of doxorubicin
DOX is a anticancer drug which exhibits maximum ﬂuores-
cence intensity at 480 nm and 560 nm of excitation and emission
Fig. 2. Binding amount of HSA and DOX versus amount of Sp.
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Fig. 3. Emission spectra and calibration curve of doxorubicin at a concentration
range of 1–10 mM.
Table 1
Amount of loaded and released DOX.
Sp, mg 5 10 15 20 25
Loaded HSA, lg 119.62 142.27 177.49 216.08 285.53
Loaded HSA, % 12.59 14.94 18.63 22.75 30.06
Released HSA, lg pH: 7.4 78.28 101.13 142.58 198.19 270.17
pH: 6 68.74 86.59 112.71 158.70 236.26
pH: 2.2 48.65 66.08 92.63 125.58 178.05
Released HSA, % pH: 7.4 65.54 71.12 80.22 91.66 95.06
pH: 6 57.14 60.56 63.27 73.15 82.88
pH: 2.2 40.33 46.48 51.98 57.87 62.57
Table 2
Amount of loaded and released DOX.
Sp, mg 5 10 15 20 25
Loaded DOX, lM 116.58 222.29 267.71 304.89 319.76
Loaded DOX, % 30.58 58.65 70.64 80.45 84.37
Released DOX, lM pH: 7.4 34.83 42.43 44.66 47.78 56.27
pH: 6 40.64 51.80 54.49 56.72 58.06
pH: 2.2 66.10 92.00 130.41 141.58 163.46
Released DOX, % pH: 7.4 30.03 19.11 16.72 15.71 17.64
pH: 6 35,03 23.33 20.40 18.66 18.20
pH: 2.2 56.98 41.44 48.84 46.57 51.24
Fig. 4. Released HSA and doxorubicin expressed as % against time (min) at pH 2.2.
Fig. 5. IR spectrum of Sp; Sp-HSA and Sp-HSA-DOX.
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measured via regression equation of the drug as viewed from inset
of Fig. 3. at a concentration range of 1 mg and10 mg. Data showed
that 20 mg and 5 mg of sporopollenin bounded 24 mg and
319.76 mM of DOX (Fig. 2).
Release of HSA from Sp particles was studied at different pH as7,4, 6 and 2,2. According to Table 1, maximum release of the
protein from sporopollenin particles has obviously been viewed at
7.4 of pH as % 95.06 at 25 mg of particles. According to Table 2,
release of DOX from Sp-HSA particles was studied at different pH
as 7,4, 6 and 2,2. Data showed that amount of released DOX has
been found as % 51.24 at 25 mg of particles. Fig. 4 showed DOX and
BSA release at optimum pH of 2.2 related to the time during 10 h
being stable.
Fig. 6. SEM images of sporopollen at 2 and 10 mm of scale.
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Fig. 7. EDX graphs and SEM images of Sp and Sp-HSA at 5 and 7 mm of scale.
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Binding procedure of albumin to sporopollenin was given at
Scheme 1. Fig. 5 illustrates FT-IR spectra of Sp and Sp-albumin
before and after binding to doxorubicin. The FT-IR spectrum of Sp
shows typical bands around at 3300 cm1 which comes fromhydroxyl groups (–OH) [38]. The peaks at around 2921 cm1 and
2858 cm1 are belong to C–H stretching vibration. The peak which
has been observed in Sp spectrum belongs to C–O stretching vi-
brations (1706 cm1) [39–41]. As seen in Fig. 5, these spectrum are
not much different from each other due to many FT-IR peaks with
similar wavelengths in Sp molecules [14]. But, several bands at
E. Maltas et al. / Biochemistry and Biophysics Reports 7 (2016) 201–205 2051191, 2925, 1710 and 1610 cm1 in FT-IR of Sp slightly shifted to
1218, 2950, 1729 and 1589 cm1 in spectra of Sp-HSA and 1303,
2921, 1741 and 1606 cm1 in spectra of Sp-HSA-DOX.
3.4. SEM and EDX
Scanning electron microscopy allowed the veriﬁcation of mor-
phological differences between sporopollenin and albumin. SEM
images of Sp at 2 and 10 mm were shown in Fig. 6a-b. As wieved
from shape of bare sporopollenin, the gaps on the Sp-HSA were
detected. After albumin immobilized on the particles, the globular
structure on Sp surface was observed at 5 mm as shown in Fig. 7a-b
because of protein binding.
EDX graphs of Sp related to SEM images that were given in
5 mm of scales (Fig. 7a-b). According to the results, C and O ratios of
Sp were found to be as 57.53% and 42.47%, respectively. After
binding of albumin to sporopollenin, nitrogen (8.98%) and sulfur
(3.14%) were introduced to EDX graphs of Sp due to protein
structure.4. Conclusion
Albumin from human serum is responsible for transport of the
drug. Therefore, albumin may be used in drug delivery systems
based on nanoparticles and polymers. In this study, Sp-HSA par-
ticles were prepared successfully with a chemical method. It is the
ﬁrst time that we have developed albumin-sporopollenin system
for doxorubicin loading in order to use drug delivery. As a result of
this study, biological macromolecules are bioavailable and bio-
compatible materials as drug carrier due to release of the drug at
different physiological pH. Therefore, newly developed Sp-HSA is
efﬁcient platform for new drugs.Acknowledgement
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